20/chembl/api/data/source?limit=20&offset=2067UndefinedUNDEFINEDThe medicinal chemistry literature provides a valuable source of bioactivity data for drug like compounds. Bioactivity data is routinely extracted from our seven core MedChem journals (Bioorg Med Chem Lett, J Med Chem, Bioorg Med Chem, J Nat Prod, Eur J Med Chem, ACS Med Chem Lett, MedChemComm) but also includes selected publications from additional journals.Scientific Literature1LITERATUREBioactivity data for a published subset of GlaxoSmithKlines compound library (the Tres Cantos antimalarial compound set (TCAMS)) screened against P. falciparum.GSK Malaria Screening2GSK_TCMDCBioactivity data for a published subset of the Novartis GNF library that was screened against P. falciparum.Novartis Malaria Screening3NOVARTISBioactivity data for a published subset of compounds from a multi-organisation antimalarial study (including St. Jude Children’s Research Hospital) screened against P. falciparum.St. Jude Children’s Research Hospital Malaria Screening4ST_JUDEThe Sanger Institute, Genomics of Drug Sensitivity in Cancer project aims to identify molecular features of cancers that predict response to anti-cancer drugs.Sanger Institute Genomics of Drug Sensitivity in Cancer5SANGERhttps://www.cancerrxgene.orgDEPRECATEDPDBe Ligands (DEPRECATED)6PDBEhttps://www.ebi.ac.uk/pdbe/PubChem is a chemistry database at the National Institutes of Health (NIH). A subset of PubChem assays were included in ChEMBL (confirmatory and panel assays with dose–response endpoints) as well as a number of assays, chosen individually, on the basis that they have been specifically requested to be included by ChEMBL usersPubChem BioAssays7PUBCHEM_BIOASSAYhttps://pubchem.ncbi.nlm.nih.govDrugs that are progressing through the phases of clinical development - clinical candidate drugs. Data are predominantly extracted from ClinicalTrials.gov via our Clinical Trials Pipeline, with a small number of manually curated clinical candidates. Clinical Candidate Compounds8CANDIDATEShttps://www.clinicaltrials.gov/FDA Orange Book database of Approved Drug Products with Therapeutic Equivalence Evaluations.FDA Orange Book Drugs9FDA_ORANGE_BOOKhttps://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-bookDEPRECATEDGuide to Receptors and Channels (DEPRECATED)10GRACOpen Toxicogenomics Project-Genomics Assisted Toxicity Evaluation Systems (TG-GATEs) is a toxicogenomics database (http://togodb.dbcls.jp/open_tggates_main). A subset of the biochemistry, in vivo and pathology measurements have been included in ChEMBL. For more information see http://toxico.nibio.go.jp/open-tggates/search.html and Mol. Nutr. Food. Res. (2010), 54(2), 218-27.Open TG-GATEs11TG_GATEShttp://togodb.dbcls.jp/open_tggates_mainFDA Novel Drug Therapy Approvals and FDA Biological License Application ApprovalsFDA Novel Drugs and Biotherapeutics12FDA_NEW_DRUGShttps://www.fda.gov/drugs/development-approval-process-drugs/novel-drug-approvals-fda; https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/biological-approvals-yearThe United States Adopted Names (USAN) Council selects simple, informative and unique nonproprietary (generic) drug names. The USAN Council establishes logical nomenclature classifications based on pharmacological and/or chemical relationships. In addition to one member-at-large and a Food and Drug Administration (FDA) liaison, the council consists of one representative from each of the following: The American Medical Association (AMA), United States Pharmacopeia (USP) and the American Pharmacists Association (APhA).United States Adopted Names (USAN)13USANhttps://www.ama-assn.org/about/united-states-adopted-namesDrugs for Neglected Diseases Initiative (DNDi) is a research organization developing new treatments for neglected patients. Deposited datasets from this initiative were provided.Drugs for Neglected Diseases Initiative (DNDi)14DNDIhttps://dndi.orgThe DrugMatrix in vitro pharmacology assays data set comprises approximately 870 therapeutic, industrial, and environmental chemicals screened against protein targets, cellular and in vivo assays at non-toxic and/or toxic doses. The DrugMatrix molecular toxicology reference database and informatics system, freely available from the US National Toxicology Program, is populated with the comprehensive results of thousands of highly controlled and standardized toxicological experiments. Following administration of these compounds in vivo, comprehensive studies of the effects of these compounds were carried out at multiple time points and in multiple target organs. The data is associated with document CHEMBL_IDs: CHEMBL2924216 (Biochemistry), CHEMBL2924217 (Hematology) and CHEMBL2924218 (Pathology).DrugMatrix15DRUGMATRIXhttps://cebs.niehs.nih.gov/cebs/paper/15670Bioactivity data associated with GSK Published Kinase Inhibitor Sets (GSK PKI).GSK Published Kinase Inhibitor Set16GSK_PKISBioactivity data associated with Screening of the MMV malaria box, a free library of 400 diverse compounds with antimalarial activity (http://www.mmv.org/malariabox).Medicines for Malaria Venture (MMV) Malaria Box17MMV_MBOXhttp://www.mmv.org/malariaboxTransporter-specific information contained in the TP-search database.TP-search Transporter Database18TP_TRANSPORTERHarvard Malaria Screening Data for liver-stage malaria from Proc. Natl. Acad. Sci. (2012), 109(22), 8511.Harvard University Malaria Screening19HARVARD